CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 181 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $2,830,221 | +627.9% | 67,434 | +488.4% | 0.02% | +433.3% |
| Q2 2023 | $388,838 | +288.5% | 11,460 | +311.9% | 0.00% | +200.0% |
| Q1 2023 | $100,096 | +44.3% | 2,782 | +78.8% | 0.00% | – |
| Q4 2022 | $69,351 | – | 1,556 | +17188.9% | 0.00% | – |
| Q3 2022 | $0 | -100.0% | 9 | -99.9% | 0.00% | -100.0% |
| Q1 2022 | $430,000 | -61.6% | 12,633 | -56.4% | 0.00% | -63.6% |
| Q4 2021 | $1,120,000 | -5.4% | 28,986 | +32.2% | 0.01% | -26.7% |
| Q3 2021 | $1,184,000 | +54.6% | 21,923 | -4.2% | 0.02% | +66.7% |
| Q2 2021 | $766,000 | +48.2% | 22,895 | -8.8% | 0.01% | +28.6% |
| Q1 2021 | $517,000 | – | 25,101 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |